# EDGAR Filing Document

**Accession Number:** 0001838821
**File Stem:** 0001140361-23-015373
**Filing Date:** 2023-3
**Character Count:** 8376
**Document Hash:** 057b018bb38e47f3b3d6d9bc475c1bd4
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001140361-23-015373.hdr.sgml**: 20230331

**ACCESSION NUMBER**: 0001140361-23-015373

**CONFORMED SUBMISSION TYPE**: NT 10-K

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20221231

**FILED AS OF DATE**: 20230331

**DATE AS OF CHANGE**: 20230331

**EFFECTIVENESS DATE**: 20230331

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ARYA Sciences Acquisition Corp IV
- **CENTRAL INDEX KEY:** 0001838821
- **STANDARD INDUSTRIAL CLASSIFICATION:** BLANK CHECKS [6770]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** NT 10-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40122
- **FILM NUMBER:** 23788261

**BUSINESS ADDRESS:**
- **STREET 1:** 51 ASTOR PLACE, 10TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10003
- **BUSINESS PHONE:** 212-284-2300

**MAIL ADDRESS:**
- **STREET 1:** 51 ASTOR PLACE, 10TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10003

------

### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### Washington, D.C. 20549
SEC FILE NUMBER: 001-40122

CUSIP NUMBER: G31659108

### FORM 12b-25

#### NOTIFICATION OF LATE FILING
(Check one): ☒ Form 10-K ☐ Form N-CSR ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR

For Period Ended: December 31, 2022

<br> ☐ Transition Report on Form 10-K

<br> ☐ Transition Report on Form 20-F

<br> ☐ Transition Report on Form 11-K

<br> ☐ Transition Report on Form 10-Q

For the Transition Period Ended:  

**Nothing in this form shall be construed to imply that the Commission has veriﬁed any information contained herein.**<br>

If the notiﬁcation relates to a portion of the ﬁling checked above, identify the Item(s) to which the notiﬁcation relates: N/A

------

#### PART I — REGISTRANT INFORMATION
ARYA SCIENCES ACQUISITION CORP IV<br>

Full Name of Registrant

N/A<br>

Former Name if Applicable

51 Astor Place, 10th Floor<br>

Address of Principal Executive Office (Street and Number)

New York, NY 10003<br>

City, State and Zip Code

#### PART II — RULES 12b-25(b) AND (c)
If the subject report could not be ﬁled without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

(a) The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;

☒ (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion thereof, will be ﬁled on or before the ﬁfteenth calendar day following
 the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be ﬁled on or before the ﬁfth calendar day following the prescribed due date;
 and

(c) The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

------

#### PART III — NARRATIVE
State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be ﬁled within the prescribed time period.

ARYA Sciences Acquisition Corp IV (the "**Company**") is unable to file, without unreasonable effort and expense, its Annual Report on Form 10-K for the year ended December 31, 2022 (the "**10-K**") because it needs additional time to complete its evaluation of certain accounting matters that have recently arisen and to complete its final review of its financial statements and other disclosures in the 10-K. The Company currently expects to file the 10-K within the fifteen-day extension period provided under Rule 12b-25 of the Securities Exchange Act of 1934, as amended.

#### Disclosures About Forward-Looking Statements
Certain statements included in this Notification of Late Filing on Form 12b-25 (the "**Notification**"), which are not historical facts, are forward-looking statements. Such forward-looking statements speak only as of the date of this Notification. These forward-looking statements can be identified by the use of forward-looking terminology, including the words "expects," "may," "will," "projects," or "should," or, in each case, their negative or other variations or comparable terminology. There can be no assurance that actual results will not materially differ from expectations. Such statements include, but are not limited to, any statements relating to our ability to consummate any acquisition or other business combination and any other statements that are not statements of current or historical facts. These statements are based on management's current expectations, but actual results may differ materially due to various factors, including, but not limited to, a variety of risk factors affecting the Company's business and prospects disclosed in the Company's annual, quarterly reports and subsequent reports filed with the SEC, as amended from time to time. The forward-looking statements contained in this Notification are based on our current expectations and beliefs concerning future developments and their potential effects on us. Future developments affecting us may not be those that we have anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control) and other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those factors described under the heading "Risk Factors" in the Company's Registration Statement on Form S-1 relating to its initial public offering, annual, quarterly reports and subsequent reports filed or to be filed with the SEC and as amended from time to time. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. These risks and others described under "Risk Factors" in the Company's Registration Statement on Form S-1 relating to its initial public offering, annual, quarterly reports and subsequent reports filed or to be filed with the SEC and as amended from time to time may not be exhaustive.

#### PART IV — OTHER INFORMATION
&nbsp;&nbsp;&nbsp;&nbsp;(1) Name and telephone number of person to contact in regard to this notiﬁcation

<u> Michael Altman </u> <u> 212 </u> <u> 284-2300 </u> <br> (Name) (Area Code) (Telephone Number)

&nbsp;&nbsp;&nbsp;&nbsp;(2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such
 shorter period that the registrant was required to ﬁle such report(s) been ﬁled? If answer is no, identify report(s). ☒ Yes ☐ No

&nbsp;&nbsp;&nbsp;&nbsp;(3) Is it anticipated that any signiﬁcant change in results of operations from the corresponding period for the last ﬁscal year will be reﬂected by the earnings statements to be included in the subject report or portion thereof? ☐ Yes ☒ No

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

------

<u> ARYA Sciences Acquisition Corp IV </u>

(Name of Registrant as Speciﬁed in Charter)

has caused this notiﬁcation to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | | | |
|:---|:---|:---|:---|:---|
| Date: | March 31, 2023 | **ARYA SCIENCES ACQUISITION CORP IV** | **ARYA SCIENCES ACQUISITION CORP IV** | **ARYA SCIENCES ACQUISITION CORP IV** |
| : |  | By | /s/ Michael Altman | /s/ Michael Altman |
|  |  |  | Name: | Michael Altman |
|  |  |  | Title: | Chief Financial Officer |

---

#### ATTENTION

#### Intentional misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001).

#### <br>

#### 3

------